The SURMOUNT-5 head-to-head trial confirmed tirzepatide outperforms semaglutide by approximately 6 percentage points on average weight loss
6 Classification of HF Several methods of classifying patients with HF have been proposed, including: categorisation according to symptom severity, 7 ejection fraction (EF), 8 or a combination of the presence of co-morbidities, symptoms, elevated blood biomarkers and structural heart alterations
Currently, tirzepatide is the most promising listed incretin analogue
GLP-1 medications accelerate fat loss, which can precipitate gallstone formation in susceptible individuals
Related Articles Get your free wellness guide Be among the first to receive science-backed wellness research, delivered weekly
The standard dose escalation schedule gradually increases doses to minimize side effects, but the first 8-16 weeks typically require the most vigilant hydration and prevention efforts